Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Abstract Background The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the tumor microenvironment that might be predictiv...
Saved in:
| Main Authors: | Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Razvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-024-01946-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
by: Richard S. Finn, et al.
Published: (2025-06-01) -
Keynotes
Published: (2025-05-01) -
Keynote Addresses
by: Marie Bilodeau
Published: (2019-12-01) -
Keynote Article
by: Zervas Efthimios
Published: (2024-01-01) -
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
by: Graham Cohen, et al.
Published: (2024-01-01)